PT - JOURNAL ARTICLE AU - Katie Rebecca Bond AU - Emily Rea AU - Charlotte Lawthom TI - Seizures in palliative medicine: brivaracetam AID - 10.1136/bmjspcare-2021-003228 DP - 2021 Jul 13 TA - BMJ Supportive & Palliative Care PG - bmjspcare-2021-003228 4099 - http://spcare.bmj.com/content/early/2021/07/12/bmjspcare-2021-003228.short 4100 - http://spcare.bmj.com/content/early/2021/07/12/bmjspcare-2021-003228.full AB - Seizures occur in around 13% of patients with cancer and can be distressing for family members to witness. In those unable to manage regular antiepileptic medications, midazolam can be administered subcutaneously using a syringe driver, but this may cause sedation. Brivaracetam is a newer drug licensed as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation and for restricted use in those with refractory epilepsy. It is associated with fewer behavioural or psychiatric side effects than levetiracetam, has a very low incidence of drug interactions and the maximal dose can be accommodated in a single syringe driver. We present three cases from 2019 to 2020 where subcutaneous brivaracetam has been successfully used in a Specialist Inpatient Palliative Care setting to manage seizures. Brivaracetam dosing is 1:1 conversion from oral:subcutaneous, with syringe driver doses ranging from 150 mg to 300 mg/24 hours being successfully used, with no adverse effects observed.